Selected research
Market Structure
Global Cyclosporine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Cyclosporine Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Cyclosporine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cyclosporine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cyclosporine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Cyclosporine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Cyclosporine Drugs include Takeda Pharmaceutical, Sun Pharmaceuticals Industries, Novartis, Huadong Medicine, Otsuka Pharmaceutical, Apotex, Allergan, AbbVie and United Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Cyclosporine Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cyclosporine Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cyclosporine Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Cyclosporine Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Cyclosporine Drugs Segment by Company
Takeda Pharmaceutical
Sun Pharmaceuticals Industries
Novartis
Huadong Medicine
Otsuka Pharmaceutical
Apotex
Allergan
AbbVie
United Biotech
Teva Pharmaceuticals Industries
Santen Pharmaceuticals
Regenerx Biopharmaceuticals
Mckesson Medical Surgical
Mayne Pharma Group
Cyclosporine Drugs Segment by Type
Oral
Parenteral
Cyclosporine Drugs Segment by Application
Dry Eye
Rheumatoid Arthritis
Transplant Rejection Prophylaxis
Psoriasis
Autoimmune Myasthenia Gravis
Others
Cyclosporine Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyclosporine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cyclosporine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyclosporine Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Cyclosporine Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cyclosporine Drugs industry.
Chapter 3: Detailed analysis of Cyclosporine Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cyclosporine Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Parenteral
Applications
- Dry Eye
- Rheumatoid Arthritis
- Transplant Rejection Prophylaxis
- Psoriasis
- Autoimmune Myasthenia Gravis
- Others
Companies covered
- Takeda Pharmaceutical
- Sun Pharmaceuticals Industries
- Novartis
- Huadong Medicine
- Otsuka Pharmaceutical
- Apotex
- Allergan
- AbbVie
- United Biotech
- Teva Pharmaceuticals Industries
- Santen Pharmaceuticals
- Regenerx Biopharmaceuticals
- Mckesson Medical Surgical
- Mayne Pharma Group
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Cyclosporine Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Oral
- 1.2.3 Parenteral
- 1.3 Market Analysis by Application
- 1.3.1 Global Cyclosporine Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Dry Eye
- 1.3.3 Rheumatoid Arthritis
- 1.3.4 Transplant Rejection Prophylaxis
- 1.3.5 Psoriasis
- 1.3.6 Autoimmune Myasthenia Gravis
- 1.3.7 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Cyclosporine Drugs Growth Trends by Region
- 1.5.1 Global Cyclosporine Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Cyclosporine Drugs Market Size by Region (2021-2026)
- 1.5.3 Cyclosporine Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Cyclosporine Drugs Market Dynamics
- 2.1 Cyclosporine Drugs Industry Trends
- 2.2 Cyclosporine Drugs Industry Drivers
- 2.3 Cyclosporine Drugs Industry Opportunities and Challenges
- 2.4 Cyclosporine Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Cyclosporine Drugs Revenue by Company (2021-2026)
- 3.2 Global Cyclosporine Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Cyclosporine Drugs Key Company Head office and Area Served
- 3.4 Global Cyclosporine Drugs Company, Product Type & Application
- 3.5 Global Cyclosporine Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Cyclosporine Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Cyclosporine Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Cyclosporine Drugs Tier 1, Tier 2, and Tier 3
4 Cyclosporine Drugs Market by Type
- 4.1 Global Cyclosporine Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Cyclosporine Drugs Market Size by Type (2021-2032)
- 4.3 Global Cyclosporine Drugs Market Size Share by Type (2021-2032)
5 Cyclosporine Drugs Market by Application
- 5.1 Global Cyclosporine Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Cyclosporine Drugs Market Size by Application (2021-2032)
- 5.3 Global Cyclosporine Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Takeda Pharmaceutical
- 6.1.1 Takeda Pharmaceutical Company Information
- 6.1.2 Takeda Pharmaceutical Business Overview
- 6.1.3 Takeda Pharmaceutical Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Takeda Pharmaceutical Cyclosporine Drugs Product Portfolio
- 6.1.5 Takeda Pharmaceutical Recent Developments
- 6.2 Sun Pharmaceuticals Industries
- 6.2.1 Sun Pharmaceuticals Industries Company Information
- 6.2.2 Sun Pharmaceuticals Industries Business Overview
- 6.2.3 Sun Pharmaceuticals Industries Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Sun Pharmaceuticals Industries Cyclosporine Drugs Product Portfolio
- 6.2.5 Sun Pharmaceuticals Industries Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Novartis Cyclosporine Drugs Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Huadong Medicine
- 6.4.1 Huadong Medicine Company Information
- 6.4.2 Huadong Medicine Business Overview
- 6.4.3 Huadong Medicine Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Huadong Medicine Cyclosporine Drugs Product Portfolio
- 6.4.5 Huadong Medicine Recent Developments
- 6.5 Otsuka Pharmaceutical
- 6.5.1 Otsuka Pharmaceutical Company Information
- 6.5.2 Otsuka Pharmaceutical Business Overview
- 6.5.3 Otsuka Pharmaceutical Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Otsuka Pharmaceutical Cyclosporine Drugs Product Portfolio
- 6.5.5 Otsuka Pharmaceutical Recent Developments
- 6.6 Apotex
- 6.6.1 Apotex Company Information
- 6.6.2 Apotex Business Overview
- 6.6.3 Apotex Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Apotex Cyclosporine Drugs Product Portfolio
- 6.6.5 Apotex Recent Developments
- 6.7 Allergan
- 6.7.1 Allergan Company Information
- 6.7.2 Allergan Business Overview
- 6.7.3 Allergan Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Allergan Cyclosporine Drugs Product Portfolio
- 6.7.5 Allergan Recent Developments
- 6.8 AbbVie
- 6.8.1 AbbVie Company Information
- 6.8.2 AbbVie Business Overview
- 6.8.3 AbbVie Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 AbbVie Cyclosporine Drugs Product Portfolio
- 6.8.5 AbbVie Recent Developments
- 6.9 United Biotech
- 6.9.1 United Biotech Company Information
- 6.9.2 United Biotech Business Overview
- 6.9.3 United Biotech Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 United Biotech Cyclosporine Drugs Product Portfolio
- 6.9.5 United Biotech Recent Developments
- 6.10 Teva Pharmaceuticals Industries
- 6.10.1 Teva Pharmaceuticals Industries Company Information
- 6.10.2 Teva Pharmaceuticals Industries Business Overview
- 6.10.3 Teva Pharmaceuticals Industries Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Teva Pharmaceuticals Industries Cyclosporine Drugs Product Portfolio
- 6.10.5 Teva Pharmaceuticals Industries Recent Developments
- 6.11 Santen Pharmaceuticals
- 6.11.1 Santen Pharmaceuticals Company Information
- 6.11.2 Santen Pharmaceuticals Business Overview
- 6.11.3 Santen Pharmaceuticals Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Santen Pharmaceuticals Cyclosporine Drugs Product Portfolio
- 6.11.5 Santen Pharmaceuticals Recent Developments
- 6.12 Regenerx Biopharmaceuticals
- 6.12.1 Regenerx Biopharmaceuticals Company Information
- 6.12.2 Regenerx Biopharmaceuticals Business Overview
- 6.12.3 Regenerx Biopharmaceuticals Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Regenerx Biopharmaceuticals Cyclosporine Drugs Product Portfolio
- 6.12.5 Regenerx Biopharmaceuticals Recent Developments
- 6.13 Mckesson Medical Surgical
- 6.13.1 Mckesson Medical Surgical Company Information
- 6.13.2 Mckesson Medical Surgical Business Overview
- 6.13.3 Mckesson Medical Surgical Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Mckesson Medical Surgical Cyclosporine Drugs Product Portfolio
- 6.13.5 Mckesson Medical Surgical Recent Developments
- 6.14 Mayne Pharma Group
- 6.14.1 Mayne Pharma Group Company Information
- 6.14.2 Mayne Pharma Group Business Overview
- 6.14.3 Mayne Pharma Group Cyclosporine Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Mayne Pharma Group Cyclosporine Drugs Product Portfolio
- 6.14.5 Mayne Pharma Group Recent Developments
7 North America
- 7.1 North America Cyclosporine Drugs Market Size (2021-2032)
- 7.2 North America Cyclosporine Drugs Market Size by Type
- 7.2.1 North America Cyclosporine Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Cyclosporine Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Cyclosporine Drugs Market Share by Type (2021-2032)
- 7.3 North America Cyclosporine Drugs Market Size by Application
- 7.3.1 North America Cyclosporine Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Cyclosporine Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Cyclosporine Drugs Market Share by Application (2021-2032)
- 7.4 North America Cyclosporine Drugs Market Size by Country
- 7.4.1 North America Cyclosporine Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Cyclosporine Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Cyclosporine Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Cyclosporine Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Cyclosporine Drugs Market Size (2021-2032)
- 8.2 Europe Cyclosporine Drugs Market Size by Type
- 8.2.1 Europe Cyclosporine Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Cyclosporine Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Cyclosporine Drugs Market Share by Type (2021-2032)
- 8.3 Europe Cyclosporine Drugs Market Size by Application
- 8.3.1 Europe Cyclosporine Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Cyclosporine Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Cyclosporine Drugs Market Share by Application (2021-2032)
- 8.4 Europe Cyclosporine Drugs Market Size by Country
- 8.4.1 Europe Cyclosporine Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Cyclosporine Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Cyclosporine Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Cyclosporine Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Cyclosporine Drugs Market Size (2021-2032)
- 9.2 China Cyclosporine Drugs Market Size by Type
- 9.2.1 China Cyclosporine Drugs Market Size by Type (2021-2026)
- 9.2.2 China Cyclosporine Drugs Market Size by Type (2027-2032)
- 9.2.3 China Cyclosporine Drugs Market Share by Type (2021-2032)
- 9.3 China Cyclosporine Drugs Market Size by Application
- 9.3.1 China Cyclosporine Drugs Market Size by Application (2021-2026)
- 9.3.2 China Cyclosporine Drugs Market Size by Application (2027-2032)
- 9.3.3 China Cyclosporine Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Cyclosporine Drugs Market Size (2021-2032)
- 10.2 Asia Cyclosporine Drugs Market Size by Type
- 10.2.1 Asia Cyclosporine Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Cyclosporine Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Cyclosporine Drugs Market Share by Type (2021-2032)
- 10.3 Asia Cyclosporine Drugs Market Size by Application
- 10.3.1 Asia Cyclosporine Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Cyclosporine Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Cyclosporine Drugs Market Share by Application (2021-2032)
- 10.4 Asia Cyclosporine Drugs Market Size by Country
- 10.4.1 Asia Cyclosporine Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Cyclosporine Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Cyclosporine Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Cyclosporine Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Cyclosporine Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Cyclosporine Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Cyclosporine Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Cyclosporine Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Cyclosporine Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Cyclosporine Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Cyclosporine Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Cyclosporine Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Cyclosporine Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Cyclosporine Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Cyclosporine Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Cyclosporine Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Cyclosporine Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Cyclosporine Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst